Indegene has announced a strategic agreement to acquire BioPharm Communications, a specialised pharmaceutical marketing and media services agency.
Under the terms of the deal, BioPharm – currently part of Omnicom Health Group – will be fully acquired by ILSL, a subsidiary of Indegene. Founded in 2005, BioPharm provides omnichannel, AI-supported marketing strategies to clients across the life sciences sector, including 17 of the world’s top 25 biopharmaceutical companies, according to the firm.
“We are very excited to join the larger Indegene family at a pivotal time for the industry”, said Steve Carickhoff, president, BioPharm. “Their life sciences-contextualised approach to AI will open up new possibilities, helping us deliver deeper value to clients. Together, we will push the boundaries of AI-powered pharma marketing worldwide – delivering more personalised, measurable and patient-focused outcomes.”
Indegene said the acquisition will enhance its commercialisation portfolio by adding BioPharm’s AdTech and digital advertising expertise. The two companies plan to co-develop AI-first, data-driven commercialisation models designed to deliver more effective, agentic operations for clients.
Manish Gupta, chairman and CEO at Indegene said: “BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialisation partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments.”